Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Depreciation and Depletion: 2019-2024

Historic Depreciation and Depletion for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to $21.9 million.

  • Beam Therapeutics' Depreciation and Depletion rose 1.55% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.1 million, marking a year-over-year increase of 1.03%. This contributed to the annual value of $21.9 million for FY2024, which is 9.56% up from last year.
  • According to the latest figures from FY2024, Beam Therapeutics' Depreciation and Depletion is $21.9 million, which was up 9.56% from $20.0 million recorded in FY2023.
  • Over the past 5 years, Beam Therapeutics' Depreciation and Depletion peaked at $21.9 million during FY2024, and registered a low of $4.7 million during FY2020.
  • Over the past 3 years, Beam Therapeutics' median Depreciation and Depletion value was $20.0 million (recorded in 2023), while the average stood at $18.7 million.
  • Data for Beam Therapeutics' Depreciation and Depletion shows a peak YoY soared of 95.76% (in 2022) over the last 5 years.
  • Over the past 5 years, Beam Therapeutics' Depreciation and Depletion (Yearly) stood at $4.7 million in 2020, then surged by 52.08% to $7.2 million in 2021, then skyrocketed by 95.76% to $14.1 million in 2022, then surged by 41.96% to $20.0 million in 2023, then grew by 9.56% to $21.9 million in 2024.